{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Merrem", "query": { "intervention": "Merrem" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 52, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Merrem&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T21:49:58.886Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01147640", "title": "Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Complicated Intra-abdominal Infection" ], "interventions": [ { "name": "CXA-101/ tazobactam and metronidazole", "type": "DRUG" }, { "name": "meropenem plus saline placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 122, "start_date": "2010-06-25", "completion_date": "2011-03-25", "has_results": true, "last_update_posted_date": "2018-10-25", "last_synced_at": "2026-09-08T21:49:58.886Z", "location_count": 11, "location_summary": "Orange, California • Torrance, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Newark", "state": "Delaware" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01147640" }, { "nct_id": "NCT03032380", "title": "Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Healthcare-associated Pneumonia (HCAP)", "Hospital Acquired Pneumonia (HAP)", "Ventilator Associated Pneumonia (VAP)" ], "interventions": [ { "name": "Cefiderocol", "type": "DRUG" }, { "name": "Meropenem", "type": "DRUG" }, { "name": "Linezolid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shionogi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 300, "start_date": "2017-10-24", "completion_date": "2019-04-01", "has_results": true, "last_update_posted_date": "2020-11-13", "last_synced_at": "2026-09-08T21:49:58.886Z", "location_count": 15, "location_summary": "New Haven, Connecticut • DeLand, Florida • Chicago, Illinois + 12 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "DeLand", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Council Bluffs", "state": "Iowa" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT03032380" }, { "nct_id": "NCT03564158", "title": "Evaluate Effects of Meropenem-Vaborbactam on QT/QTc in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "meropenem-vaborbactam", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 53, "start_date": "2018-05-01", "completion_date": "2018-11-19", "has_results": false, "last_update_posted_date": "2019-01-10", "last_synced_at": "2026-09-08T21:49:58.886Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03564158" }, { "nct_id": "NCT06672978", "title": "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Pyelonephritis", "Complicated Urinary Tract Infection" ], "interventions": [ { "name": "Meropenem-Vaborbactam", "type": "DRUG" }, { "name": "Antibiotics", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": "11 Years", "sex": "ALL", "summary": "3 Months to 11 Years" }, "enrollment_count": 66, "start_date": "2025-06-03", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-08T21:49:58.886Z", "location_count": 4, "location_summary": "Little Rock, Arkansas • Orange, California • Omaha, Nebraska + 1 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Orange", "state": "California" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06672978" }, { "nct_id": "NCT01445678", "title": "Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Complicated Intra-abdominal Infection" ], "interventions": [ { "name": "CXA-201 and metronidazole", "type": "DRUG" }, { "name": "Meropenem", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 494, "start_date": "2011-12-23", "completion_date": "2013-10-15", "has_results": true, "last_update_posted_date": "2018-11-16", "last_synced_at": "2026-09-08T21:49:58.886Z", "location_count": 4, "location_summary": "Springfield, Illinois • Boston, Massachusetts • Robbinsdale, Minnesota + 1 more", "locations": [ { "city": "Springfield", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Robbinsdale", "state": "Minnesota" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01445678" }, { "nct_id": "NCT00050401", "title": "Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pneumonia" ], "interventions": [ { "name": "MERREM I.V. 2g as a 3 hour infusion every 8 hours", "type": "DRUG" }, { "name": "vancomycin I.V. 1 g every 12 hours", "type": "DRUG" }, { "name": "tobramycin I.V. 5 mg/kg every 24 hours", "type": "DRUG" }, { "name": "MERREM I.V. 1g as a 30 minute infusion every 8 hours", "type": "DRUG" }, { "name": "MERREM I.V. 500 mg as a 3 hour infusion every 8 hours", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 500, "start_date": "2002-07", "completion_date": "2004-09", "has_results": false, "last_update_posted_date": "2017-09-01", "last_synced_at": "2026-09-08T21:49:58.886Z", "location_count": 10, "location_summary": "Phoenix, Arizona • Newark, Delaware • Indianapolis, Indiana + 7 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Newark", "state": "Delaware" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00050401" }, { "nct_id": "NCT00752219", "title": "Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Complicated Intra-abdominal Infections" ], "interventions": [ { "name": "ceftazidime/NXL104 + metronidazole", "type": "DRUG" }, { "name": "meropenem", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 204, "start_date": "2009-03-31", "completion_date": "2009-12-31", "has_results": true, "last_update_posted_date": "2018-07-03", "last_synced_at": "2026-09-08T21:49:58.886Z", "location_count": 9, "location_summary": "Los Angeles, California • Palm Springs, California • Detroit, Michigan + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Butte", "state": "Montana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00752219" }, { "nct_id": "NCT04692181", "title": "SYN-004 Safety and Tolerability in Allo-HCT Subjects", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant", "Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics" ], "interventions": [ { "name": "SYN-004, Ribaxamase or Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Theriva Biologics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2021-02-15", "completion_date": "2030-09-30", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-09-08T21:49:58.886Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04692181" }, { "nct_id": "NCT05977868", "title": "Comparing Oral Versus Parenteral Antimicrobial Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Endovascular Infection", "Bone and Joint Infection", "Skin and Soft Tissue Infection", "Pulmonary Infection", "Gastrointestinal Infection", "Genitourinary Infection" ], "interventions": [ { "name": "Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid", "type": "DRUG" }, { "name": "Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "West Virginia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2023-08-04", "completion_date": "2025-02-14", "has_results": true, "last_update_posted_date": "2025-08-26", "last_synced_at": "2026-09-08T21:49:58.886Z", "location_count": 1, "location_summary": "Morgantown, West Virginia", "locations": [ { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05977868" }, { "nct_id": "NCT01110382", "title": "A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Abscess, Intra-Abdominal", "Abdominal Abscess", "Abdomen, Acute", "Abdominal Pain", "Appendicitis", "Rupture", "Infection", "Intestinal Perforation", "Peritonitis", "Ileus" ], "interventions": [ { "name": "Doripenem", "type": "DRUG" }, { "name": "Meropenem placebo", "type": "DRUG" }, { "name": "Meropenem", "type": "DRUG" }, { "name": "Doripenem placebo", "type": "DRUG" }, { "name": "Amoxicillin/clavulanate potassium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Months", "maximum_age": "18 Years", "sex": "ALL", "summary": "3 Months to 18 Years" }, "enrollment_count": 41, "start_date": "2010-12", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2014-07-15", "last_synced_at": "2026-09-08T21:49:58.886Z", "location_count": 4, "location_summary": "San Diego, California • Washington D.C., District of Columbia • Cleveland, Ohio + 1 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Toledo", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01110382" } ] }